CG Oncology stock
CGONNASDAQCG Oncology Inc., HealthcareISIN US1569441009
41Score 41 out of 100, Weak
Price and trend
81 / 100
Price history
+78% in one yearThe chart shows daily closes over 3 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 5.4% above it.
Since September 2025 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 63).
The price is 13% below its 52-week high. Largest decline in 3 years: 67% (February 2024 to April 2025).
Chart figures for advanced users
- SMA 50$68.04
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$66.57
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)63
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$37.37
- The lowest closing price of the last twelve months.
- Resistance$80.68
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- CG Oncology Inc. belongs to the Biotechnology industry (United States) and, with a market value of $6.27B, is number 61 of 296 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $4.04M (up 254.7% year on year) and a loss of $161M.
- MEQIRI Score 41 out of 100 (Weak): rank 535 of 714 in Healthcare, median 53.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- More cash than debtCash $984.46M, financial debt $9.24M.Stability 72
Weaknesses
- Revenue shrinkingRevenue down 21% a year since 2021.Growth 32
- Loss-makingLoss of $237.46M over the last 12 months.Fundamentals 17
- Negative free cash flowFree cash flow −$189.17M over the last 12 months.Fundamentals 17
Its standout strengths are technical analysis and momentum, while fundamentals and profitability hold the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansValuation
Valuation signal
not measuredClosing price of 11 Nov 2026, used by the daily score.
No fair value can be calculated for this stock, so the signal follows the valuation grade.
Valuation metrics
No fair value can be calculated for this stock from the available figures.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In fiscal 2025, revenue rose 255% on the prior year. Revenue has declined since 2021 (-21% per year), so it is worth watching closely.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross −15%, operating −4722%, net −3985%. Last 12 months: net −100%.
Debt & balance sheet
latest quarterDebt is low; no interest coverage is reported.
Earnings
- Next earnings
- 26 Feb 2027in 106 days
- Last reported
- 6 Nov 2026EPS reported −$0.64 (expected −$0.83)above expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- −$3.320.0%
- Revenue
- $4.34M+0.3%
- Earnings per share
- −$3.130.0%
- Revenue
- $80.64M0.0%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Insiders
Open-market purchases and sales by executives, board members and major holders
One insider bought on the open market in the last 6 months, $24.81M in total. 2 insiders sold, $2.91M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Post Leonard ESale
15 Oct 2026, Board
- Shares
- 1,000
- Price
- $62.07
- Value
- $62,065
- Post Leonard ESale
15 Sept 2026, Board
- Shares
- 1,000
- Price
- $72.98
- Value
- $72,980
- Post Leonard ESale
14 Aug 2026, Board
- Shares
- 1,000
- Price
- $74.54
- Value
- $74,540
Show 7 more
- Post Leonard ESale
15 Jul 2026, Board
- Shares
- 1,000
- Price
- $71.17
- Value
- $71,170
- Mulay JamesSale
10 Jul 2026, Board
- Shares
- 24,165
- Price
- $75.16
- Value
- $1.82M
- Liu Brian Guan-ChyunPurchase
25 Jun 2026, Board
- Shares
- 371,085
- Price
- $66.87
- Value
- $24.81M
- Post Leonard ESale
24 Jun 2026, Board
- Shares
- 5,000
- Price
- $70.00
- Value
- $350,000
- Post Leonard ESale
22 Jun 2026, Board
- Shares
- 5,000
- Price
- $65.00
- Value
- $325,000
- Mulay JamesSale
15 Jun 2026, Board
- Shares
- 1,310
- Price
- $60.12
- Value
- $78,757
- Post Leonard ESale
4 Jun 2026, Board
- Shares
- 1,000
- Price
- $54.50
- Value
- $54,500
Partial trades from one filing are shown in one row, with the average price.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at CG Oncology
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 41
- Sector median
- 53
Categories against the sector medianMedian of 714 companies
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- Caris Life SciencesCAI $7.02B58
- Arrowhead PharmaceuticalsARWR $6.97B32
- Kodiak SciencesKOD $6.87B43
- Samsung Epis Holdings0126Z0.KS $6.58B41
- BioconBIOCON.NS $6.4B41
- Ligand PharmaceuticalsLGND $6.34B61
- Belite BioBLTE $6.27B41
- Hangzhou Tigermed Consulting300347.SZ $6.21B47
ETFs that hold CG Oncology
Held by 13 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| iShares Healthcare Innovation UCITS ETF2B78 | 0.45% | 0.40% | €1.49B |
| iShares Nasdaq US Biotechnology UCITS ETF2B70 | 0.38% | 0.35% | €1.21B |
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.18% | 0.30% | €2.17B |
Show 5 more
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.18% | 0.30% | €4.22B |
| iShares MSCI USA Small Cap CTB Enhanced ESG UCITS ETFSXRG | 0.04% | 0.43% | €2.48B |
| iShares MSCI World Small Cap UCITS ETFIUSN | 0.03% | 0.35% | €8.19B |
| iShares MSCI World Small Cap CTB Enhanced ESG UCITS ETFCBUG | 0.02% | 0.35% | €434.1M |
| UBS MSCI USA Select Factor Mix UCITS ETF USD accUSUE | 0.01% | 0.25% | €175.89M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 24 Jan 2025)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.